David Malcom Rodman - 11 Oct 2024 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Medical Officer
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
11 Oct 2024
Net transactions value
+$8,489
Form type
4
Filing time
15 Oct 2024, 16:22:13 UTC
Previous filing
12 Sep 2024
Next filing
08 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Options Exercise $2,709 +5,017 +4% $0.5400 130,622 11 Oct 2024 Direct
transaction MLYS Common Stock Options Exercise $5,780 +5,352 +4.1% $1.08 135,974 14 Oct 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Options Exercise $0 -5,017 -25% $0.000000 15,052 11 Oct 2024 Common Stock 5,017 $0.5400 Direct F1
transaction MLYS Stock Option Options Exercise $0 -5,352 -3.1% $0.000000 165,434 14 Oct 2024 Common Stock 5,352 $1.08 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
F2 The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.